Nanjing-based Neurodawn Pharmaceutical Co., Ltd has entered into a significant licensing deal with China Medical System Holdings (CMS; HKG: 0867), a fellow Chinese firm. The agreement grants CMS exclusive promotion rights for Neurodawn’s anti-ischemic stroke brain cell protective agent, Y-3, across mainland China, Hong Kong, and Macau.
Y-3: A Promising Small-Molecule Drug for Stroke Recovery
The Category 1 small-molecule drug, Y-3, is designed to enhance neurological symptoms, daily living activities, and address functional impairments resulting from acute ischemic stroke. Y-3 stands out as the sole non-peptide PSD95-nNOS uncoupling agent currently in clinical development. It has successfully completed Phase I trials in China, demonstrating a favorable safety profile, and has progressed into Phase II trials.
Expanding Access to Y-3 with CMS Partnership
This strategic licensing agreement with China Medical System Holdings is a pivotal move for Neurodawn Pharmaceutical, ensuring broader access to Y-3 for patients in need across the Greater China region. The partnership is expected to leverage CMS’s extensive network and expertise to expedite the drug’s market penetration and patient accessibility.-Fineline Info & Tech
